Sandoz's Biosimilar Acceleration Is the Story - Guidance Confirmation Is Just the Footnote

Headlines today focus on Sandoz backing its full-year outlook. That's the part of the results that won't change your portfolio. The part that might is the acceleration curve in its biosimilars business, which grew 22% at constant currency in the second quarter - faster than H1 2025's 12%, and faster than the 6.7% full-year growth rate management is guiding to. When a segment doubles its growth rate in one year while pulling up overall margins, the guidance confirmation is the lagging indicator.

Sandoz released H1 2026 results today (August 5), and the numbers show a company in the middle of a structural shift. Q2 net sales reached $3.0 billion, up 7% at constant currency, driven almost entirely by biosimilars, which delivered $1.02 billion on that 22% growth rate. Generics - still the larger revenue bucket at $1.98 billion - grew 1%. In the first half overall, net sales came in at $5.76 billion, up 5% at constant currency. Core EBITDA margin (earnings before interest, tax, depreciation, and amortization, stripped of one-offs - a rough proxy for operating cash generation) expanded to 20.9%, up 90 basis points from H1 2025's 20.0%. EPS grew 11% at constant currency to $1.71 for the half, and free cash flow nearly doubled to $337 million from $207 million.

The biosimilars growth trajectory is what you need to track. H1 2025: 12% constant-currency growth. Q2 2026: 22%. That is an improving report card, not a blip. And the mix shift is equally structural: biosimilars now represent 33% of total net sales in H1 2026, versus 29% a year ago and 30% for full-year 2025. North America is the engine, with biosimilar growth of 47% at constant currency in the first half, pulled by recent launches of Wyost and Jubbonti (denosumab biosimilars competing against Amgen's Prolia/Xgeva). Sandoz has moved from third to second in North American biosimilar-and-generic gross sales, which means its distribution and formulary access are scaling alongside the product launches.

What does this mean for the rating? The growth factor is upgrading. Last year, Sandoz was a steady-but-slow generics name with a biosimilar option. Now it's a biosimilar-growth story with a generics base. That changes the comparison set. Against Teva Pharmaceutical, which still trades at a negative P/E and a 20.5x EV/EBITDA on a much less profitable and less differentiated portfolio, Sandoz's 19.4x forward P/E as of late July looks like the premium for a business that is actually executing on the transition everyone in the space has been talking about. Sandoz's normalized P/E per Morningstar sits around 24x, and consensus EPS estimates have been revised upward from $1.27 to $1.44 - a 13% upward revision that is independent of today's headline.

The valuation question is whether that forward multiple is justified if the biosimilar growth rate holds. At 22% CC growth in Q2, the biosimilars segment is growing fast enough that even a gradually shifting mix will push overall company growth materially higher. The 6.7% full-year CC guidance from management is conservative relative to the Q2 inflection - H2 will need to deliver roughly 8.4% CC growth to hit that target, and Q2 alone grew 7% at the company level with biosimilars well above that. Unless the generics base meaningfully deteriorates, the guidance looks like a floor, not a ceiling.

The generics side is the real risk. At 1% CC growth in Q2, the traditional business is flat after years of price erosion and market consolidation. That's why the biosimilar mix shift matters - it's not just growth, it's insurance. As biosimilars move toward 35% or more of total sales, the weighted-average growth rate of the combined business tilts higher even if generics stay flat. The margin expansion of 90 basis points in H1 confirms that the mix shift is profitable, not just volumetric.

Management free cash flow held steady at $503 million for the half, while reported free cash flow (the stricter measure that includes capex) doubled to $337 million. That's driven by stronger operating cash generation and disciplined working capital, not accounting shifts. Capital expenditures increased in H1 as Sandoz builds out its vertically integrated biosimilar manufacturing platform, which is still a work in progress. The pipeline now holds 36 in-house biosimilar candidates after adding four this year, and the company is building a new biosimilar development center in Ljubljana, Slovenia.

What to watch next. Sandoz is joining the Swiss Market Index on September 21 - the country's blue-chip index - which will force passive fund flows into the stock and increase institutional visibility. The Capital Markets Day in London on September 8 will be the next catalyst for detail on the "golden decade" strategy Saynor has been telegraphing. If management raises guidance at the CMD or shows the biosimilar growth rate holding above 20% across more segments, the case for re-rating strengthens. If Q3 biosimilar growth falls back toward the Q1 pace of 18%, the thesis isn't broken but the urgency would be lower.

Portfolio role: Sandoz belongs in a quality-growth sleeve focused on healthcare companies that are transitioning from commoditized businesses to differentiated ones. It's the generics-to-biosimilars trade, and it's one of the few names in the space where the transition is actually showing on the income statement. The stock sits between a dividend-value profile - Sandoz pays a meaningful dividend - and a growth trajectory that could pull it toward higher multiples if the biosimilar momentum persists. It hedges against the narrative that biosimilars are just cheaper drugs facing the same pricing pressure as generics; Sandoz's margin expansion and pipeline depth argue otherwise.

The trigger to reassess: if biosimilar growth decelerates below 15% CC for two consecutive quarters, or if the generics business starts declining at more than 3% CC, the quality premium justifies less. If growth stays at or above the Q2 pace through H2, the forward 19x multiple starts looking narrow for what's essentially a 20%+ growth business with room to expand margins further.

The factor stack says the business is improving, the valuation isn't stretched relative to the growth it's actually delivering, and the catalyst calendar over the next four weeks could compress the timeline. That's the setup worth paying attention to.